A number of clinical trials in type 2 diabetic patients with different degrees of renal impairment have clearly demonstrated that SGLT2 inhibitors reduce the progression rate of diabetic kidney disease. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.